全文获取类型
收费全文 | 19673篇 |
免费 | 1627篇 |
国内免费 | 84篇 |
学科分类
医药卫生 | 21384篇 |
出版年
2023年 | 93篇 |
2022年 | 140篇 |
2021年 | 534篇 |
2020年 | 273篇 |
2019年 | 443篇 |
2018年 | 492篇 |
2017年 | 342篇 |
2016年 | 409篇 |
2015年 | 487篇 |
2014年 | 648篇 |
2013年 | 822篇 |
2012年 | 1315篇 |
2011年 | 1320篇 |
2010年 | 732篇 |
2009年 | 617篇 |
2008年 | 1142篇 |
2007年 | 1146篇 |
2006年 | 1094篇 |
2005年 | 1042篇 |
2004年 | 1059篇 |
2003年 | 880篇 |
2002年 | 882篇 |
2001年 | 387篇 |
2000年 | 355篇 |
1999年 | 345篇 |
1998年 | 201篇 |
1997年 | 179篇 |
1996年 | 161篇 |
1995年 | 122篇 |
1994年 | 133篇 |
1993年 | 144篇 |
1992年 | 291篇 |
1991年 | 256篇 |
1990年 | 210篇 |
1989年 | 197篇 |
1988年 | 188篇 |
1987年 | 186篇 |
1986年 | 172篇 |
1985年 | 158篇 |
1984年 | 123篇 |
1983年 | 104篇 |
1982年 | 84篇 |
1981年 | 83篇 |
1980年 | 94篇 |
1979年 | 88篇 |
1978年 | 87篇 |
1977年 | 79篇 |
1976年 | 93篇 |
1973年 | 96篇 |
1972年 | 89篇 |
排序方式: 共有10000条查询结果,搜索用时 434 毫秒
1.
2.
3.
4.
5.
William G. Breen Krishan R. Jethwa Nathan Y. Yu Grant M. Spears William S. Harmsen Robert C. Miller Jonathan B. Ashman William G. Rule Terence T. Sio Michelle A. Neben-Wittich Michael G. Haddock Amit Mahipal Mark J. Truty Christopher L. Hallemeier Kenneth W. Merrell 《Practical radiation oncology》2021,11(1):e63-e69
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment. 相似文献
6.
7.
Ki Wook Kim Digby W. Allen Thomas Briese Jennifer J. Couper Simon C. Barry Peter G. Colman Andrew M. Cotterill Elizabeth A. Davis Lynne C. Giles Leonard C. Harrison Mark Harris Aveni Haynes Jessica L. Horton Sonia R. Isaacs Komal Jain Walter I. Lipkin Kelly McGorm Grant Morahan Claire Morbey Ignatius C. N. Pang Anthony T. Papenfuss Megan A. S. Penno Richard O. Sinnott Georgia Soldatos Rebecca L. Thomson Peter Vuillermin John M. Wentworth Marc R. Wilkins William D. Rawlinson Maria E. Craig 《Pediatric diabetes》2020,21(2):271-279
8.
9.
10.
Hsin-Yi Tseng Jan Dreyer Abdullah Al Emran Dilini Gunatilake Mehdi Pirozyan Carleen Cullinane Ken Dutton-Regester Helen Rizos Nicholas K. Hayward Grant McArthur Peter Hersey Jessamy Tiffen Stuart Gallagher 《International journal of cancer. Journal international du cancer》2020,147(8):2176-2189
The treatment of melanoma has been markedly improved by the introduction of targeted therapies and checkpoint blockade immunotherapy. Unfortunately, resistance to these therapies remains a limitation. Novel anticancer therapeutics targeting the MCL1 anti-apoptotic protein have shown impressive responses in haematological cancers but are yet to be evaluated in melanoma. To assess the sensitivity of melanoma to new MCL1 inhibitors, we measured the response of 51 melanoma cell lines to the novel MCL1 inhibitor, S63845. Additionally, we assessed combination of this drug with inhibitors of the bromodomain and extra-terminal (BET) protein family of epigenetic readers, which we postulated would assist MCL1 inhibition by downregulating anti-apoptotic targets regulated by NF-kB such as BCLXL, BCL2A1 and XIAP, and by upregulating pro-apoptotic proteins including BIM and NOXA. Only 14% of melanoma cell lines showed sensitivity to S63845, however, combination of S63845 and I-BET151 induced highly synergistic apoptotic cell death in all melanoma lines tested and in an in vivo xenograft model. Cell death was dependent on caspases and BAX/BAK. Although the combination of drugs increased the BH3-only protein, BIM, and downregulated anti-apoptotic proteins such as BCL2A1, the importance of these proteins in inducing cell death varied between cell lines. ABT-199 or ABT-263 inhibitors against BCL2 or BCL2 and BCLXL, respectively, induced further cell death when combined with S63845 and I-BET151. The combination of MCL1 and BET inhibition appears to be a promising therapeutic approach for metastatic melanoma, and presents opportunities to add further BCL2 family inhibitors to overcome treatment resistance. 相似文献